340 related articles for article (PubMed ID: 7781266)
1. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
[TBL] [Abstract][Full Text] [Related]
2. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
Sohn DR; Kwon JT; Kim HK; Ishizaki T
Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
[TBL] [Abstract][Full Text] [Related]
3. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
[TBL] [Abstract][Full Text] [Related]
4. The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism.
Kortunay S; Basci NE; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
Eur J Clin Pharmacol; 1997; 53(3-4):261-4. PubMed ID: 9476042
[TBL] [Abstract][Full Text] [Related]
5. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Rost KL; Brockmöller J; Esdorn F; Roots I
J Hepatol; 1995 Sep; 23(3):268-77. PubMed ID: 8550990
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.
Ishizaki T; Chiba K; Manabe K; Koyama E; Hayashi M; Yasuda S; Horai Y; Tomono Y; Yamato C; Toyoki T
Clin Pharmacol Ther; 1995 Aug; 58(2):155-64. PubMed ID: 7648765
[TBL] [Abstract][Full Text] [Related]
8. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
9. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
[TBL] [Abstract][Full Text] [Related]
10. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
[TBL] [Abstract][Full Text] [Related]
11. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
[TBL] [Abstract][Full Text] [Related]
12. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
[TBL] [Abstract][Full Text] [Related]
13. Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.
Kimura M; Ieiri I; Wada Y; Mamiya K; Urae A; Iimori E; Sakai T; Otsubo K; Higuchi S
Br J Clin Pharmacol; 1999 Jan; 47(1):115-9. PubMed ID: 10073749
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
[TBL] [Abstract][Full Text] [Related]
15. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin.
Rost KL; Brösicke H; Brockmöller J; Scheffler M; Helge H; Roots I
Clin Pharmacol Ther; 1992 Aug; 52(2):170-80. PubMed ID: 1505152
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.
Böttiger Y; Tybring G; Götharson E; Bertilsson L
Clin Pharmacol Ther; 1997 Oct; 62(4):384-91. PubMed ID: 9357389
[TBL] [Abstract][Full Text] [Related]
17. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
Tybring G; Böttiger Y; Widén J; Bertilsson L
Clin Pharmacol Ther; 1997 Aug; 62(2):129-37. PubMed ID: 9284848
[TBL] [Abstract][Full Text] [Related]
18. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation.
Brockmöller J; Rost KL; Gross D; Schenkel A; Roots I
Pharmacogenetics; 1995 Apr; 5(2):80-8. PubMed ID: 7663532
[TBL] [Abstract][Full Text] [Related]
19. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity.
Shu Y; Wang LS; Xu ZH; He N; Xiao WM; Wang W; Huang SL; Zhou HH
J Pharmacol Exp Ther; 2000 Nov; 295(2):844-51. PubMed ID: 11046127
[TBL] [Abstract][Full Text] [Related]
20. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
Sim SC; Risinger C; Dahl ML; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
Clin Pharmacol Ther; 2006 Jan; 79(1):103-13. PubMed ID: 16413245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
